go to japanese page

Clinical Efficacy of Oral Amoxicillin 1,500 mg in the Treatment of Syphilis
1)Department of Infectious Diseases, Tokyo Metropolitan Komagome Hospital, 2)Department of Infection Prevention and Control, Tokyo Metropolitan Komagome Hospital, 3)Department of Clinical Laboratory Medicine, Tokyo Medical University Hospital, 4)Center for Health and the Global Environment, Department of Environmental Health, Harvard T.H. Chan School of Public Health, 5)Toshima Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation
Kazuhiko IKEUCHI1), Kazuaki FUKUSHIMA1), Masaru TANAKA1), Keishiro YAJIMA1), Noritaka SEKIYA2), Ryoko SEKIYA3), Naoki YANAGISAWA4), Atsushi AJISAWA1)5) & Akifumi IMAMURA1)
(Received July 18, 2017)
(Accepted January 25, 2018)
Key words: syphilis, amoxicillin

Although intramuscular benzathine penicillin G is a standard treatment for syphilis in many countries, it is not available in Japan. Instead, The Japanese Society for Sexually Transmitted Diseases recommends a therapeutic regimen using 1,500 mg of oral amoxicillin (AMPC) for syphilis treatment. However, the efficacy of this treatment regimen has not been evaluated sufficiently in the past literature. We conducted a retrospective observational study including 63 patients who were diagnosed as having syphilis (47 HIV patients; median age 40 years) and treated with 1,500 mg of oral AMPC. Treatment success was defined as a 4-fold decline in the rapid plasma reagin (RPR) titer within one year after the initiation of the treatment. The overall treatment efficacy was 95.2% (95% confidence interval (CI), 86.7-99.0%). The efficacy for HIV patients, non-HIV patients, early syphilis and late syphilis was 95.7% (95% CI, 85.5-99.5%), 93.8% (95% CI, 69.8-99.8%), 97.8% (95% CI, 88.5-99.9%) and 88.2% (95% CI, 63.6-98.5%), respectively. Our data suggests that 1,500 mg of oral AMPC was shown to be effective for syphilis.

[ Kansenshogaku Zasshi 92: 358-364, 2018 ]

To read the PDF file you will need Adobe Reader installed on your computer.